NOVO — Marts 2026
-
ElMiller 21:45 - Novo har stadig søgsmålet og kan aktivere det, hvis de finder det nødigt! - Hvad Mike D. ikke mente, det blev... Jeg er ellers enig: Det ser ikke ud til at være forhandlet godt nok: Men HIMS er vigtig for distributionen og dermed volumen! Og volumen er alt, det drejer sig om nu!
-
Novo Nordisk betaler yderligere 50 mio. dollar til udviklingspartner https://proinvestor.com/investornyt/1419581/novo-nordisk-betaler-yderligere-50-mio-dollar-til-udviklingspartner
-
Novo: Amerikansk børshus skruer anbefalingen ned til neutralt niveau
https://proinvestor.com/investornyt/1419580/novo-amerikansk-borshus-skruer-anbefalingen-ned-til-neutralt-niveau -
Novo Nordisk's 'Semaglutide' gains weight against Eli Lilly in battle for market share
Novo Nordisk's 'Semaglutide' gains weight against Eli Lilly in battle for market share
Novo Nordisk's diabetes and weight-loss drug semaglutide is rapidly gaining ground in India. It is now challenging Eli Lilly's tirzepatide in the anti-obesity market. Price reductions and increased availability are driving this surge. Semaglutide's market share has significantly increased, narrowing the gap with its competitor. This trend is expected to continue as Novo Nordisk expands its reach.
The Economic Times (economictimes.indiatimes.com)
-
Novo Nordisk Is Slashing Prices for Ozempic and Wegovy. Here's Why That Might End Up Helping the Stock https://www.fool.com/investing/2026/03/09/novo-nordisk-is-slashing-prices-for-ozempic-and-we/
-
Eli Lilly says some Medicare plans may exceed $50 cap for weight-loss drugs https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-says-some-medicare-plans-may-exceed-50-cap-weight-loss-drugs-2026-03-09/
-
Novos aftale med Hims & Hers giver begrænset rygstød mener amerikanske storbank https://proinvestor.com/investornyt/1419590/novos-aftale-med-hims-hers-giver-begraenset-rygstod-mener-amerikanske-storbank
-
Video: Denne episode af The Downsized News gennemgår flere vigtige udviklinger i den hastigt udviklende verden af GLP-1-medicin og fedmebehandling. Christopher og Laraine Durham gennemgår den seneste forskning, regulatoriske tiltag og brancheændringer, der påvirker folk, der bruger medicin som Zepbound, Mounjaro, Wegovy og Ozempic til at behandle fedmesygdommen. https://proinvestor.com/boards/131485
-
As federal regulators intensify scrutiny of compounded GLP-1 drugs and telehealth marketing practices, two developments in early March 2026 signal a turning point for the industry: a wave of FDA enforcement actions and a high-profile resolution between Hims & Hers Health and Novo Nordisk. https://www.frierlevitt.com/articles/fda-warning-letters-hims-novo-nordisk-compounded-glp1/
-
Novo Nordisk bekræfter advarselsbrev fra FDA https://proinvestor.com/investornyt/1419761/novo-nordisk-bekraefter-advarselsbrev-fra-fda
-
Ad PN 16:47 - Så FDA kritiserer Novos bivirknings-systemer i denne tid, hvor semaglutid eksploderer globalt. Har Novo ikke styr på det? PS Novo fik observationerne i feb 2025 og har haft omkring et år (!) til at adressere dem, før FDA valgte at sende et egentligt advarselsbrev. Er det normalt? Og besynderligt, at modsat Novo, så kunne FDA identificere afdøde….
-
Novo USA Statement vedr FDA https://www.novonordisk-us.com/media/news-archive/news-details.html
-
Grupo Santander has initiated coverage of $NVO with an Outperform rating.
The bank also sets a price target of DKK 366.84.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind